<DOC>
	<DOCNO>NCT01648608</DOCNO>
	<brief_summary>Select postmenopausal patient breast cancer confirm core needle biopsy clinical stage T2-4N0-2M0.Treat 4 cycle TAC neoadjuvant chemotherapy ( Docetaxel 75mg/m2 , EPI 60mg/m2 CTX 600mg/m2,21day/cycle ) .At time give daily oral exemestane 25mg 12 weeks.Then ass efficacy safety TAC Exemestane .</brief_summary>
	<brief_title>Efficacy Safety TAC Exemestane Neoadjuvant Chemotherapy Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description>The investigator select postmenopausal patient breast cancer confirm core needle biopsy clinical stage T2-4N0-2M0.Treat 4 cycle TAC neoadjuvant chemotherapy ( Docetaxel 75mg/m2 , EPI 60mg/m2 CTX 600mg/m2,21day/cycle ) .At time give daily oral exemestane 25mg 12 weeks.Then ass efficacy safety TAC Exemestane .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>1 . Karnofsky ≥ 70 2 . Provision inform consent 3 . Pathological confirmation invasive ductal carcinoma estrogen receptor positive 4 . Tumor stage ( TNM ) : T24bN03M0 5 . Premenopausal woman 6 . Not previously receive treatment bisphosphonate 7 . Laboratory criterion : PLT ≥ 100*109/L WBC ≥ 4000/mm3 HGB ≥ 10g/dl GOT , GPT , ALP ≤ 2*ULN TBIL , DBIL , CCr ≤ 1.5*ULN 1 . Pregnant lactation woman 2 . History organ transplantation 3 . With mental disease 4 . With severe infection active gastrointestinal ulcer 5 . With severe liver disease ( cirrhosis ) , kidney disease , respiratory disease diabetes 6 . Diseasefree period malignant tumor le 5 year ( except cure basal cell skin cancer cervical carcinoma situ ) 7 . With heart disease 8 . Experimental drug allergy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>